3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Hemangioma
3
Urinary Bladder Neoplasms
2
Sarcoma, Kaposi
2
Sarcoma
2
Multiple Myeloma
2
Melanoma
2
Hemangiosarcoma
2
Hemangioma, Cavernous, Central Nervous System
2
Breast Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
Sirolimus
7
Everolimus
5
ganaxolone
1
dactolisib
1
Vigabatrin
1
Sertraline
1
Selective Serotonin Reuptake Inhibitors
1
Propranolol
1
Aspirin
1
Anticonvulsants
1
2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tuberous Sclerosis
×
Propranolol
×
Clear all
NCT02104011
2026-05-19
STBETA
University Hospital, Bordeaux
Phase 2
Completed
2 enrolled